Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...

Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...

Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” ...

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.